お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
987556

医薬品連続生産の世界市場:2021-2028年

Global Pharmaceutical Continuous Manufacturing Market Forecast 2021-2028

出版日: | 発行: Inkwood Research | ページ情報: 英文 205 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.37円
医薬品連続生産の世界市場:2021-2028年
出版日: 2021年02月08日
発行: Inkwood Research
ページ情報: 英文 205 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の医薬品連続生産の市場規模は予測期間中10.23%のCAGRで成長すると予測されています。医薬品連続生産システムの導入の拡大、連続生産システムの採用推進のための政府の取り組み、新興市場の開発の機会、高分子薬および生物製剤の生産量の増加、医療費の拡大などの要因が同市場の成長を推進しています。

当レポートでは、世界の医薬品連続生産の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制環境、市場規模の推移・予測、製品・用途・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 調査範囲・調査手法

第2章 エグゼクティブサマリー

  • 市場規模・推計
  • 市場概要

第3章 市場力学

  • 主な成長推進因子
  • 主な制約

第4章 主要分析

  • ポーターのファイブフォース分析
  • COVID-19の影響
  • 規制の枠組み
  • 市場機会マトリックス
  • ベンダー情勢
  • 投資分析

第5章 市場分析・予測:製品別

  • 統合型連続システム
  • 半連続システム
  • 制御・ソフトウェア

第6章 市場分析・予測:用途別

  • 最終医薬品製造
  • API製造

第7章 市場分析・予測:エンドユーザー別

  • 製薬企業
  • CMO
  • その他

第8章 市場分析・予測:地域・主要国別

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第9章 競合情勢

  • 主な戦略的展開
  • 企業プロファイル
    • COPERION GMBH
    • ELI LILLY & COMPANY
    • GEA GROUP AG
    • GEBRUDER LODIGE MASCHINENBAU GMBH
    • GLATT GMBH
    • HOSOKAWA MICRON CORPORATION
    • KORSCH AG
    • LB BOHLE MASCHINEN + VERFAHREN GMBH
    • MUNSON MACHINERY COMPANY
    • PFIZER INC
    • SIEMENS HEALTHINEERS
    • SYNTEGON (FORMERLY BOSCH PACKAGING TECHNOLOGY)
    • THERMO FISHER SCIENTIFIC INC
図表

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - PHARMACEUTICAL CONTINUOUS MANUFACTURING
  • TABLE 2: PROJECTED NATIONAL HEALTHCARE EXPENDITURE, 2021-2028 (IN $ BILLION)
  • TABLE 3: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 4: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 5: GLOBAL INTEGRATED CONTINUOUS SYSTEM MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 6: GLOBAL INTEGRATED CONTINUOUS SYSTEM MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 7: GLOBAL SEMI-CONTINUOUS SYSTEM MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 8: GLOBAL SEMI-CONTINUOUS SYSTEM MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 9: GLOBAL CONTROL & SOFTWARE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 10: GLOBAL CONTROL & SOFTWARE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 11: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 12: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 13: GLOBAL FINAL DRUG PRODUCT MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 14: GLOBAL FINAL DRUG PRODUCT MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 15: GLOBAL API MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 16: GLOBAL API MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 17: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 18: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 19: GLOBAL PHARMACEUTICAL COMPANIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 20: GLOBAL PHARMACEUTICAL COMPANIES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 21: GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 22: GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 23: GLOBAL OTHER END-USERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 24: GLOBAL OTHER END-USERS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 25: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 26: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 27: NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 28: NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 29: LEADING PLAYERS OPERATING IN NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET
  • TABLE 30: EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 31: EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 32: LEADING PLAYERS OPERATING IN EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET
  • TABLE 33: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 34: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 35: LEADING PLAYERS OPERATING IN ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET
  • TABLE 36: REST OF WORLD PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 37: REST OF WORLD PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 38: LEADING PLAYERS OPERATING IN REST OF WORLD PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, IN 2020
  • FIGURE 6: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY INTEGRATED CONTINUOUS SYSTEM, 2021-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY SEMI-CONTINUOUS SYSTEM, 2021-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY CONTROL & SOFTWARE, 2021-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, IN 2020
  • FIGURE 10: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY FINAL DRUG PRODUCT MANUFACTURING, 2021-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY API MANUFACTURING, 2021-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, IN 2020
  • FIGURE 13: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PHARMACEUTICAL COMPANIES, 2021-2028 (IN $ MILLION)
  • FIGURE 14: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2021-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY OTHER END-USERS, 2021-2028 (IN $ MILLION)
  • FIGURE 16: NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 17: UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 18: CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 19: EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 20: GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 21: FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 22: UNITED KINGDOM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 23: ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 24: RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 25: BELGIUM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 26: POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 27: REST OF EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 28: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 29: CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 30: INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 31: JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 32: AUSTRALIA & NEW ZEALAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 33: SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 34: THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 35: INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 36: VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 37: REST OF ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 38: REST OF WORLD PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 39: LATIN AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 40: MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
目次
Product Code: 30916

KEY FINDINGS

The global pharmaceutical continuous manufacturing market is anticipated to register a CAGR of 10.23%, during the studied period of 2021 to 2028. The market growth is facilitated by key drivers, such as, the increasing adoption of pharmaceutical continuous manufacturing systems, the government initiatives for adopting continuous manufacturing systems, the opportunities for development across emerging markets, the rising production of large molecules and biologics, and the increasing healthcare expenditure.

MARKET INSIGHTS

Continuous manufacturing entails an advanced manufacturing approach conducted by employing end-to-end integration of manufacturing subprocesses, along with a substantial level of control strategies.

The growth of the global pharmaceutical continuous manufacturing market is anticipated to be fueled by the opportunities across the untapped and emerging markets, owing to the availability of enhanced pharmaceutical infrastructure, the increased demand for pharmaceutical continuous manufacturing systems, and the growing number of pharmaceutical industries. Moreover, emerging countries' healthcare industry is also augmenting at a considerable rate, given the increased demand for advanced manufacturing systems, as well as notable government investments, in order to improve the healthcare infrastructure.

REGIONAL INSIGHTS

The global pharmaceutical continuous manufacturing market growth is evaluated by studying the Asia Pacific, North America, Europe, and the rest of the Asia Pacific. The Asia Pacific is anticipated to grow with the highest CAGR over the forecast period, owing to factors such as, the augmenting contract research organization (CRO) and contract manufacturing organization (CMO), and growing investments across the region's pharmaceutical and biopharmaceutical industry.

COMPETITIVE INSIGHTS

Although the industry growth of the pharmaceutical continuous manufacturing market is high, the product differentiation is considerably low. Besides, key players are reluctant to divest from their businesses. With a substantial amount of investment involved, the exit barriers are moderately difficult. As a result, the degree of competitive rivalry is projected as moderate to high, over the forecast period.

Some of the key players operating in the market are, Korsch AG, Pfizer Inc, Eli Lilly & Company, Siemens Healthineers, Thermo Fisher Scientific Inc, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. KEY DRIVERS
    • 3.1.1. DEVELOPMENT OPPORTUNITIES IN UNTAPPED EMERGING MARKETS
    • 3.1.2. INCREASED ADOPTION OF PHARMACEUTICAL CONTINUOUS MANUFACTURING SYSTEMS
    • 3.1.3. RISING GOVERNMENT INITIATIVES FOR THE ADOPTION OF CONTINUOUS MANUFACTURING SYSTEMS
    • 3.1.4. RISE IN PRODUCTION OF LARGE MOLECULES AND BIOLOGICS
    • 3.1.5. INCREASE IN THE HEALTHCARE EXPENDITURE
  • 3.2. KEY RESTRAINTS
    • 3.2.1. INCREASING CUSTOMER ANTICIPATIONS
    • 3.2.2. LACK OF DEMAND FOR CONTINUOUS MANUFACTURING SYSTEMS IN UNDERDEVELOPED COUNTRIES

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. IMPACT OF COVID-19 ON PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET
  • 4.3. REGULATORY FRAMEWORK
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. VENDOR LANDSCAPE
  • 4.6. KEY INVESTMENT INSIGHTS

5. MARKET BY PRODUCT

  • 5.1. INTEGRATED CONTINUOUS SYSTEM
  • 5.2. SEMI-CONTINUOUS SYSTEM
  • 5.3. CONTROL & SOFTWARE

6. MARKET BY APPLICATION

  • 6.1. FINAL DRUG PRODUCT MANUFACTURING
  • 6.2. API MANUFACTURING

7. MARKET BY END-USER

  • 7.1. PHARMACEUTICAL COMPANIES
  • 7.2. CONTRACT MANUFACTURING ORGANIZATIONS
  • 7.3. OTHER END-USERS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. MARKET SIZE & ESTIMATES
    • 8.1.2. KEY GROWTH ENABLERS
    • 8.1.3. KEY CHALLENGES
    • 8.1.4. KEY PLAYERS
    • 8.1.5. COUNTRY ANALYSIS
      • 8.1.5.1. UNITED STATES
      • 8.1.5.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. MARKET SIZE & ESTIMATES
    • 8.2.2. KEY GROWTH ENABLERS
    • 8.2.3. KEY CHALLENGES
    • 8.2.4. KEY PLAYERS
    • 8.2.5. COUNTRY ANALYSIS
      • 8.2.5.1. GERMANY
      • 8.2.5.2. FRANCE
      • 8.2.5.3. UNITED KINGDOM
      • 8.2.5.4. ITALY
      • 8.2.5.5. RUSSIA
      • 8.2.5.6. BELGIUM
      • 8.2.5.7. POLAND
      • 8.2.5.8. REST OF EUROPE
  • 8.3. ASIA PACIFIC
    • 8.3.1. MARKET SIZE & ESTIMATES
    • 8.3.2. KEY GROWTH ENABLERS
    • 8.3.3. KEY CHALLENGES
    • 8.3.4. KEY PLAYERS
    • 8.3.5. COUNTRY ANALYSIS
      • 8.3.5.1. CHINA
      • 8.3.5.2. INDIA
      • 8.3.5.3. JAPAN
      • 8.3.5.4. AUSTRALIA & NEW ZEALAND
      • 8.3.5.5. SOUTH KOREA
      • 8.3.5.6. THAILAND
      • 8.3.5.7. INDONESIA
      • 8.3.5.8. VIETNAM
      • 8.3.5.9. REST OF ASIA PACIFIC
  • 8.4. REST OF WORLD
    • 8.4.1. MARKET SIZE & ESTIMATES
    • 8.4.2. KEY GROWTH ENABLER
    • 8.4.3. KEY CHALLENGE
    • 8.4.4. KEY PLAYERS
    • 8.4.5. REGIONAL ANALYSIS
      • 8.4.5.1. LATIN AMERICA
      • 8.4.5.2. MIDDLE EAST & AFRICA

9. COMPETITIVE LANDSCAPE

  • 9.1. KEY STRATEGIC DEVELOPMENTS
    • 9.1.1. MERGER & ACQUISITIONS
    • 9.1.2. PRODUCT LAUNCH & DEVELOPMENTS
    • 9.1.3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
    • 9.1.4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
  • 9.2. COMPANY PROFILE
    • 9.2.1. COPERION GMBH
    • 9.2.2. ELI LILLY & COMPANY
    • 9.2.3. GEA GROUP AG
    • 9.2.4. GEBRUDER LODIGE MASCHINENBAU GMBH
    • 9.2.5. GLATT GMBH
    • 9.2.6. HOSOKAWA MICRON CORPORATION
    • 9.2.7. KORSCH AG
    • 9.2.8. LB BOHLE MASCHINEN + VERFAHREN GMBH
    • 9.2.9. MUNSON MACHINERY COMPANY
    • 9.2.10. PFIZER INC
    • 9.2.11. SIEMENS HEALTHINEERS
    • 9.2.12. SYNTEGON (FORMERLY BOSCH PACKAGING TECHNOLOGY)
    • 9.2.13. THERMO FISHER SCIENTIFIC INC
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.